ArticleJournal of clinical microbiology2011
Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles.
Article in Journal of clinical microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Guideline
- In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.American journal of ophthalmology · 2014Trial
- Mycological Survey of Fungal Carriage in Cats and Their Owners: Analysis of Species Diversity and Antifungal Susceptibility.Journal of fungi (Basel, Switzerland) · 2026Article
- Comprehensive Review of Environmental Surveillance for Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- A prospective, multicenter study of invasive fungal disease caused by molds in children and adults in Chile.PloS one · 2025Article
- Hospital distribution, seasonality, time trends and antifungal susceptibility profiles of all Aspergillus species isolated from clinical samples from 2015 to 2022 in a tertiary care hospital.BMC microbiology · 2024Article
- Trends in the activity of mold-active azole agents againstJournal of clinical microbiology · 2024Article
- Epidemiology of Invasive Candidiasis.Clinical epidemiology · 2024Review
- 4-Allyl-2-methoxyphenol modulates the expression of genes involved in efflux pump, biofilm formation and sterol biosynthesis in azole resistantFrontiers in cellular and infection microbiology · 2023Article
- Species Distribution and Antifungal Susceptibilities ofJournal of clinical microbiology · 2022Article
- Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019).The Journal of antibiotics · 2021Article
- A 20-Year Antifungal Susceptibility Surveillance (From 1999 to 2019) forFrontiers in microbiology · 2021Article
- Invasive Aspergillosis byJournal of fungi (Basel, Switzerland) · 2019Review
- Antifungal Resistance in Clinical Isolates ofJournal of fungi (Basel, Switzerland) · 2019Article
- Relevance of heterokaryosis for adaptation and azole-resistance development in Aspergillus fumigatus.Proceedings. Biological sciences · 2019Article
- Environmental Isolates of Multi-Azole-ResistantJournal of fungi (Basel, Switzerland) · 2018Article
- Diagnostic Aspects of Veterinary and Human Aspergillosis.Frontiers in microbiology · 2018Article
- Triazole phenotypes and genotypic characterization of clinical Aspergillus fumigatus isolates in China.Emerging microbes & infections · 2017Article
- Article
- Genetic Diversity andAntimicrobial agents and chemotherapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the absence of clinical breakpoints, epidemiological cutoff values (ECVs) have been established to distinguish wild-type (WT) isolates of Aspergillus spp. from those that may harbor resistance mutations. Recently, the CLSI has developed ECVs for triazoles (itraconazole, posaconazole, and voriconazole) and common Aspergillus species. We applied the triazole ECVs to 1,789 Aspergillus isolates collected from 63 centers worldwide from 2001 to 2009 to determine the frequency of non-WT strains of each species. Temporal trends were evaluated for Aspergillus fumigatus and Aspergillus flavus over the 9-year period for each drug. The collection included 1,312 isolates of A. fumigatus, 235 of A. flavus, 162 of Aspergillus niger, 64 of Aspergillus terreus, and 15 of Aspergillus versicolor. Using the ECVs, the percentages of non-WT isolates for itraconazole, posaconazole, and voriconazole, respectively, were as follows: A. fumigatus (2.0%, 3.5%, and 1.4%), A. flavus (0.8%, 5.1%, and 1.7%), A. niger (17.3%, 3.7%, and 0.6%), A. terreus (0.0%, 1.6%, and 3.2%), and A. versicolor (6.3%, 0.0%, and 0.0%). Among 49 Aspergillus isolates for which itraconazole MICs were >2 μg/ml, the posaconazole and voriconazole MICs were greater than the ECVs for 14 and 12 isolates, respectively. The percentages of isolates for which MICs were greater than the ECVs ranged from 1.1 to 5.7% for posaconazole, 0.0 to 1.6% for voriconazole, and 0.7 to 4.0% for itraconazole. There was no consistent trend toward decreased susceptibility for any triazole and A. fumigatus or A. flavus over time. Decreased susceptibility among Aspergillus spp. was observed for each of the extended-spectrum triazoles and varied by species over the 9-year study period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.